GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (NAS:RENB) » Definitions » 5-Year Yield-on-Cost %

RENB (Renovaro) 5-Year Yield-on-Cost % : 0.00 (As of Sep. 20, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Renovaro 5-Year Yield-on-Cost %?

Renovaro's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for Renovaro's 5-Year Yield-on-Cost % or its related term are showing as below:



RENB's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.69
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Renovaro's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Renovaro's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renovaro's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovaro's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Renovaro's 5-Year Yield-on-Cost % falls into.



Renovaro 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Renovaro is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Renovaro  (NAS:RENB) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Renovaro 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Renovaro's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovaro Business Description

Traded in Other Exchanges
Address
2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.
Executives
Leni Boeren director 2080 CENTURY PARK EAST, #906, LOS ANGELES CA 90067
Ruud Hendriks director CHATEAU D'AZUR, BLVD D'LTALIE 44, MONACO O9 C11298000
Ole Abildgaard 10 percent owner VEDBAEK STRANDVEJ 506, VEDBAEK G7 2950
Francois Binette officer: Executive Vice President 2022 N. ALVARADO STREET, LOS ANGELES CA 90039
Serhat Gumrukcu 10 percent owner 2080 CENTURY CITY EAST, SUITE 906, LOS ANGELES CA 90067
Rene Sindlev director, 10 percent owner FRUEBJERGVEJ 3 BOX 62, COPENHAGEN G7 2100
Carl Forest Sandler other: Former director see note below 330 EAST 33RD STREET, APARTMENT 3A, NEW YORK FL 10016
Jayne Mcnicol director 606 NORTHERN AVENUE, MILL VALLEY CA 94941
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Carol L Brosgart director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Henrik Gronfeldt-sorensen director STUMPEDYSSEVEJ 17, HORSHOLM G7 2970
Luisa Puche officer: Chief Financial Officer 318 NE 104TH STREET, MIAMI FL 33138
Luc Debruyne director NOORDENWINDHELLING 2 02/05, OOSTDUINKERKE C9 8670
Anderson Wittekind William 10 percent owner 8581 SANTA MONICA BLVD, LOS ANGELES CA 90069
Leire, Eric Jean Marie director, officer: CEO; President C/O DANDRIT BIOTECH USA, INC., P.O. BOX 189, RANDOLPH VT 05060

Renovaro Headlines